ABP-201 / AstraZeneca, Abpro, Abpro Bio - LARVOL DELTA

[VIRTUAL] A tetravalent bispecific anti-angiopoietin-2/anti-VEGF antibody suppresses neovascular lesion and leakage in a laser-induced rat choroidal neovascularization model (ARVO 2021) - " Brown-Norway rats received a single 5 µL intravitreal injection of ABP-201 in three concentrations, vehicle, or aflibercept (EYLEA®) in the right eye. Our study demonstrated that ABP-201 was beneficial for reducing neovascular lesion formation and vascular leakage in rat model of laser-induced CNV. These results pave the way to begin to utilize this bispecific antibody, engineered to improve both efficacy and durability compared to current VEGF therapies, for the treatment of wet-AMD and DME, as well as other angiogenic eye diseases."

Preclinical • Age-related Macular Degeneration • Diabetic Macular Edema • Diabetic Retinopathy • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration